Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Avidity Biosciences Inc 10578 SCIENCE CENTER DRIVE SUITE 125 SAN DIEGO CA 92121 USA

www.aviditybiosciences.com P: 858-401-7900

Description:

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.

Key Statistics

Overview:

Market Capitalization, $K 1,836,726
Enterprise Value, $K 1,651,646
Shares Outstanding, K 79,719
Annual Sales, $ 9,560 K
Annual Net Income, $ -212,220 K
Last Quarter Sales, $ 2,190 K
Last Quarter Net Income, $ -60,440 K
EBIT, $ -235,600 K
EBITDA, $ -244,770 K
60-Month Beta 0.78
% of Insider Shareholders 2.00%
Float, K 78,125
% Float 98.00%
Short Volume Ratio 0.54

Growth:

1-Year Return 40.57%
3-Year Return 2.49%
5-Year Return 0.00%
5-Year Revenue Growth 2,415.79%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.79 on 02/28/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -2.90
EPS Growth vs. Prev Qtr -11.27%
EPS Growth vs. Prev Year 10.23%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -39.74%
Return-on-Assets % -34.98%
Profit Margin % -2,219.87%
Debt/Equity 0.00
Price/Sales 196.38
Price/Cash Flow N/A
Price/Book 3.54
Book Value/Share 6.76
Interest Coverage -2.92
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar